Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study

Blood (2023) 142 (Supplement 1): 1800.

https://doi.org/10.1182/blood-2023-173132

Published: 2023

Journal Articles

French National Retrospective Cohort of Hairy-Cell Leukemias: Risk of Second Malignancies after 10 Years of Follow-up

Blood (2019) 134 (Supplement_1): 1537.

https://doi.org/10.1182/blood-2019-127560

Published: 2019

Journal Articles

Clonal Selection in Therapy Related Myelodysplastic Syndromes Under Azacitidine Treatment

Anne Calleja, Chimene Moreilhon, PhD, Jean Michel Karsenti, MD, Lauris Gastaud, MD, Lionel Mannone, MD, Berengere Dadone, MD, Guillaume Robert, PhD, Patrick Auberger, PhD, Sophie Raynaud, MD PhD, Thomas Cluzeau, MDPhD

Blood (2017) 130 (Supplement 1): 5297.

https://doi.org/10.1182/blood.V130.Suppl_1.5297.5297

Published: 2017

Journal Articles

Hemoglobin Level at Azacitidine Onset Is a Prognostic Factor of Unachievement of Three Azacitidine Cycles in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Anne Calleja, Jean Michel Karsenti, Lauris Gastaud, MD, Georges Garnier, Jean Gutnecht, Daniel Re, MD, Laurence Legros, MD PhD, Lionel Mannone, Patrick Auberger, PhD, Sophie Raynaud, MD, Thomas Cluzeau, MD PhD

Blood (2016) 128 (22): 5529.

https://doi.org/10.1182/blood.V128.22.5529.5529

Published: 2016

Journal Articles

BCL2L10 Quantification Is a Predictive Factor of Response to Azacitidine in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Valerie Vidal, Clemence Ginet, Jean Michel Karsenti, MD, Frederic Luciano, PhD, Lauris Gastaud, MD, Georges Garnier, MD, Thorsten Braun, MD, Pierre Hirsch, MD, Emmanuel Raffoux, MD, Anne Marie Nloga, Herve Dombret, MD, Pierre-Simon Rohrlich, Lionel Ades, MD PhD, Christine Chomienne, MD PhD, Pierre Fenaux, MD PhD, Patrick Auberger, PhD, Guillaume Robert, PhD, Thomas Cluzeau, MD PhD

Blood (2014) 124 (21): 3261.

https://doi.org/10.1182/blood.V124.21.3261.3261

Published: 2014

Journal Articles

Evaluation Of Acadesine, a Drug Stimulating Cell Autophagy, In Azacitidine(AZA)-Resistant Myelodysplastic Syndromes (MDS)

Thomas Cluzeau, MD, PhD, Guillaume Robert, PhD, Jean Michel Karsenti, MD, Frederic Luciano, PhD, Nicolas Mounier, MD, PhD, Jill Patrice Cassuto, MD, PhD, Lionel Ades, Sophie Raynaud, MD, PhD, Pierre Fenaux, MD, PhD, Patrick Auberger, PhD

Blood (2013) 122 (21): 1568.

https://doi.org/10.1182/blood.V122.21.1568.1568

Published: 2013

Journal Articles

Azacitidine Overcomes Prognosis Impact of Poor and Very Poor IPSS-Revised in RAEB-2 Patients but Not in AML Patients.

Thomas Cluzeau, MD, PhD, Nicolas Mounier, MD, PhD, Valentine Richez, Jean-Michel Karsenti, MD, Faezeh Legrand, MD, PhD, Lionel Mannone, MD, Henri Vinti, MD, Laurence Legros, MD, PhD, Lauris Gastaud, Antoine Thyss, MD, Georges Garnier, MD, Daniel Re, MD, Nathalie Montagne, MD, Jean Gutnecht, MD, Patrick Auberger, MD, PhD, Sophie Raynaud, Jill-Patrice Cassuto, MD

Blood (2012) 120 (21): 2813.

https://doi.org/10.1182/blood.V120.21.2813.2813

Published: 2012

Journal Articles

Total Genomic Loss Detected by High-Density Single Nucleotide Polymorphism Array Is Predictive of Azacitidine Response in Very Poor IPSS-Revised MDS or AML Patients

Thomas Cluzeau, MD, PhD, Chimène Moreilhon, Nicolas Mounier, MD, PhD, Jean-Michel Karsenti, MD, Lionel Mannone, MD, Faezeh Legrand, MD, PhD, Valentine Richez, Lauris Gastaud, Antoine Thyss, MD, Georges Garnier, MD, Daniel Re, MD, Nathalie Montagne, MD, Jean Gutnecht, MD, Patrick Auberger, MD, PhD, Jill-Patrice Cassuto, MD, Sophie Raynaud

Blood (2012) 120 (21): 4936.

https://doi.org/10.1182/blood.V120.21.4936.4936

Published: 2012

Journal Articles

Tyrosine Kinase Inhibitor-Mediated Apoptosis Is Potentiated by FasL and Increased with IFN-α in Chronic Myeloid Leukemia

Laurence Legros, MD, PhD, Nathalie Ebran, PhD, Jean-Michel Karsenti, MD, Faezeh Legrand, MD, PhD, Lionel Mannone, MD, Nicolas Mounier, MD, PhD, Henri Vinti, MD, Jill-Patrice Cassuto, MD, Pierre-Simon Rohrlich, MD, PhD, Anne-Odile Hueber, PhD

Blood (2012) 120 (21): 4428.

https://doi.org/10.1182/blood.V120.21.4428.4428

Published: 2012

Journal Articles

BCL2L10 (Bcl-B) Is Associated with Resistance to Azacitidine (AZA) in MDS and AML, and Is a Possible Therapeutic Target in AZA Resistant Patients

Thomas Cluzeau, MD, PhD, Guillaume Robert, Jean-Michel Karsenti, MD, Frederic Luciano, Alexandre Puissant, Faezeh Legrand, MD, PhD, Lionel Mannone, MD, Aline Renneville, MD, Claude Preudhomme, Pierre Fenaux, MD, PhD, Jill-Patrice Cassuto, MD, Sophie Raynaud, Nicolas Mounier, MD, PhD, Patrick Auberger, MD, PhD

Blood (2012) 120 (21): 701.

https://doi.org/10.1182/blood.V120.21.701.701

Published: 2012

Journal Articles

Correlation Between Outcome and Genetic Abnormalities Identified by High-Density Single Nucleotide Polymorphism Array Analysis In Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia with Multi-Lineage Dysplasia Treated with Azacitidine

Thomas Cluzeau, Chimène Moreilhon, Nicolas Mounier, Jean-Michel Karsenti, Lionel Mannone, Henri Vinti, Laurence Legros, MD, Antoine Thyss, Georges Garnier, Jean Gutnecht, Daniel Re, MD, Patrick Auberger, Jill-Patrice Cassuto, S. Dominique Raynaud, MD

Blood (2010) 116 (21): 2929.

https://doi.org/10.1182/blood.V116.21.2929.2929

Published: 2010

Journal Articles

Induction of Autophagic Cell Death Circumvents Azacitidine-Resistance In Myelodysplastic Syndrome-Derived Cell Lines

Thomas Cluzeau, Guillaume Robert, Jean-Michel Karsenti, Frederic Luciano, Alexandre Puissant, S. Dominique Raynaud, MD, Lionel Mannone, Jill-Patrice Cassuto, Nicolas Mounier, Patrick Auberger

Blood (2010) 116 (21): 1817.

https://doi.org/10.1182/blood.V116.21.1817.1817

Published: 2010

Journal Articles

Treatment of MDS with Excess Blasts by Bevacizumab Is Well Tolerated and Is Associated with a Decrease of VEGF Plasma Level.

Laurence Legros, Boranne Slama, Jean-Michel Karsenti, Norbert Vey, Shanti Natarajan-Ame, Eric Watel, Bruno Richard, Krimo Bouabdallah, Lionnel Mannone, Irit Touitou, Sebastien Huault, Jerome Durivault, Anne-Odile Hueber, Jean-Francois Michiels, Pierre Fenaux, Francois Dreyfus

Blood (2009) 114 (22): 2770.

https://doi.org/10.1182/blood.V114.22.2770.2770

Published: 2009

Journal Articles

Single Treatment with Rituximab Monotherapy for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with Extended Follow-Up (F/Up) of 7 Years.

Blood (2006) 108 (11): 486.

https://doi.org/10.1182/blood.V108.11.486.486

Published: 2006

Journal Articles

Single 4-Dose Rituximab Treatment for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with a Follow-Up (F/Up) of at Least 5 Years.

Blood (2004) 104 (11): 585.

https://doi.org/10.1182/blood.V104.11.585.585

Published: 2004

NARROW

Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study

French National Retrospective Cohort of Hairy-Cell Leukemias: Risk of Second Malignancies after 10 Years of Follow-up

Clonal Selection in Therapy Related Myelodysplastic Syndromes Under Azacitidine Treatment

Hemoglobin Level at Azacitidine Onset Is a Prognostic Factor of Unachievement of Three Azacitidine Cycles in Myelodysplastic Syndromes and Acute Myeloid Leukemia

BCL2L10 Quantification Is a Predictive Factor of Response to Azacitidine in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Evaluation Of Acadesine, a Drug Stimulating Cell Autophagy, In Azacitidine(AZA)-Resistant Myelodysplastic Syndromes (MDS)

Azacitidine Overcomes Prognosis Impact of Poor and Very Poor IPSS-Revised in RAEB-2 Patients but Not in AML Patients.

Total Genomic Loss Detected by High-Density Single Nucleotide Polymorphism Array Is Predictive of Azacitidine Response in Very Poor IPSS-Revised MDS or AML Patients

Tyrosine Kinase Inhibitor-Mediated Apoptosis Is Potentiated by FasL and Increased with IFN-α in Chronic Myeloid Leukemia

BCL2L10 (Bcl-B) Is Associated with Resistance to Azacitidine (AZA) in MDS and AML, and Is a Possible Therapeutic Target in AZA Resistant Patients

Correlation Between Outcome and Genetic Abnormalities Identified by High-Density Single Nucleotide Polymorphism Array Analysis In Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia with Multi-Lineage Dysplasia Treated with Azacitidine

Induction of Autophagic Cell Death Circumvents Azacitidine-Resistance In Myelodysplastic Syndrome-Derived Cell Lines

Treatment of MDS with Excess Blasts by Bevacizumab Is Well Tolerated and Is Associated with a Decrease of VEGF Plasma Level.

Single Treatment with Rituximab Monotherapy for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with Extended Follow-Up (F/Up) of 7 Years.

Single 4-Dose Rituximab Treatment for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with a Follow-Up (F/Up) of at Least 5 Years.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only